Carbapenemase-producing Enterobacterales infections: recent advances in diagnosis and treatment

被引:34
|
作者
Lee, Yu-Lin [1 ,2 ]
Chen, Hsien-Meng [1 ]
Hii, Ing-Moi [1 ]
Hsueh, Po-Ren [3 ,4 ,5 ,6 ,7 ]
机构
[1] Changhua Christian Hosp, Dept Internal Med, Changhua, Taiwan
[2] Natl Chung Hsing Univ, Inst Genom & Bioinformat, Taichung, Taiwan
[3] China Med Univ, China Med Univ Hosp, Sch Med, Dept Lab Med, Taichung, Taiwan
[4] China Med Univ, China Med Univ Hosp, Sch Med, Dept Internal Med, Taichung, Taiwan
[5] China Med Univ, Sch Med, PhD Program Aging, Taichung, Taiwan
[6] Natl Taiwan Univ, Dept Lab Med, Natl Taiwan Univ Hosp, Coll Med, Taipei, Taiwan
[7] Natl Taiwan Univ, Dept Internal Med, Natl Taiwan Univ Hosp, Coll Med, Taipei, Taiwan
关键词
Multidrug resistance; Carbapenemase; Enterobacterales; Rapid diagnostics; IN-VITRO ACTIVITY; CARBA NP TEST; DESORPTION IONIZATION-TIME; URINARY-TRACT-INFECTIONS; FLIGHT MASS-SPECTROMETRY; CEFTAZIDIME-AVIBACTAM; INACTIVATION METHOD; RAPID DETECTION; DOUBLE-BLIND; RESISTANT ENTEROBACTERIACEAE;
D O I
10.1016/j.ijantimicag.2022.106528
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Increasing carbapenem resistance in Enterobacterales poses a threat to public health. In recent decades, this increase in carbapenem resistance has been caused by the global dissemination of carbapenemase-producing Enterobacterales (CPE). Carbapenemases are members of the beta-lactamases that are divided into classes A, B and D based on their molecular structures. Although certain traditionally used antibiotics, such as amikacin, polymyxins, tigecycline and fosfomycin, may remain effective against some CPE, their clinical use is limited owing to adverse effects, including renal toxicity, tissue penetration or the requirement for combination treatment. Recently, several novel agents have been approved for clinical use, such as ceftazidime/avibactam, ceftolozane/tazobactam, cefiderocol, eravacycline, omadacycline, meropenem/vaborbactam, imipenem/cilastatin/relebactam and plazomicin. However, the spectrum of antimicrobial activities and efficacies of novel agents vary depending on the mechanisms associated with carbapenem resistance in Enterobacterales. Therefore, it is of utmost importance to enable accurate and rapid diagnosis of CPE infection, including the determination of their antimicrobial resistance mechanisms. Here, recent advances in methods for the identification of CPE have been reviewed, including phenotypic methods (carbapenemase inactivation methods), biochemical methods [Carbapenemase Nordmann-Poirel (Carba NP) test and modified Carba NP test], immunochromatographic methods, proteomic methods [matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF/MS)] and molecular-based methods [nucleic acid amplification technologies, hybridisation techniques (microarray) and whole-genome sequencing]. Both precise diagnosis and adequate treatment are important to combat the emerging CPE crisis. (c) 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Treatment of infections caused by carbapenemase-producing Enterobacterales
    Inigo, Melania
    Del Pozo, Jose Luis
    [J]. REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 : 46 - 50
  • [2] Carbapenemase-producing Enterobacterales infections in COVID-19 patients
    Pintado, Vicente
    Ruiz-Garbajosa, Patricia
    Escudero, Rosa
    Gioia, Francesca
    Herrera, Sabina
    Vizcarra, Pilar
    Fortun, Jesus
    Cobo, Javier
    Martin-Davila, Pilar
    Isabel Morosini, Maria
    Canton, Rafael
    Moreno, Santiago
    [J]. INFECTIOUS DISEASES, 2022, 54 (01) : 36 - 45
  • [3] The Changing Epidemiology of Carbapenemase-Producing Enterobacterales
    Hussein, Khetam
    Geffen, Yuval
    Eluk, Orna
    Warman, Sigal
    Aboalheja, Worood
    Alon, Tamar
    Firan, Ibrahim
    Paul, Mical
    [J]. RAMBAM MAIMONIDES MEDICAL JOURNAL, 2022, 13 (01):
  • [4] Treatment and Outcomes of Infections Caused by Diverse Carbapenemase-Producing Carbapenem-Resistant Enterobacterales
    Lim, Fang Kang
    Liew, Yi Xin
    Cai, Yiying
    Lee, Winnie
    Teo, Jocelyn Q. M.
    Lay, Wei Qi
    Chung, Jasmine
    Kwa, Andrea L. H.
    [J]. FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2020, 10
  • [5] Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections
    Vrancianu, Corneliu Ovidiu
    Dobre, Elena Georgiana
    Gheorghe, Irina
    Barbu, Ilda
    Cristian, Roxana Elena
    Chifiriuc, Mariana Carmen
    [J]. MICROORGANISMS, 2021, 9 (04)
  • [6] Recent advances in the laboratory detection of carbapenemase-producing Enterobacteriaceae
    Matsumura, Yasufumi
    Pitout, Johann D.
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (07) : 783 - 794
  • [7] The seasonality of carbapenemase-producing Enterobacterales in South Korea
    Kim, J. Y.
    Park, S.
    Kim, E. O.
    Chang, E.
    Bae, S.
    Kim, M. J.
    Chong, Y. P.
    Choi, S-H.
    Lee, S-O.
    Kim, Y. S.
    Jung, J.
    Kim, S-H.
    [J]. JOURNAL OF HOSPITAL INFECTION, 2023, 140 : 87 - 89
  • [8] Susceptibility of carbapenemase-producing Enterobacterales (CPE) to nitroxoline
    Fuchs, Frieder
    Hamprecht, Axel
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (10) : 2934 - 2937
  • [9] Hospital effluent: A reservoir for carbapenemase-producing Enterobacterales?
    Cahill, Niamh
    O'Connor, Louise
    Mahon, Blathnaid
    Varley, Aine
    McGrath, Elaine
    Ryan, Phelim
    Cormican, Martin
    Brehony, Carina
    Jolley, Keith A.
    Maiden, Martin C.
    Brisse, Sylvain
    Morris, Dearbhsile
    [J]. SCIENCE OF THE TOTAL ENVIRONMENT, 2019, 672 : 618 - 624
  • [10] Carbapenemase-Producing Enterobacterales in Algeria: A Systematic Review
    Touati, Abdelaziz
    Mairi, Assia
    [J]. MICROBIAL DRUG RESISTANCE, 2020, 26 (05) : 475 - 482